A Study to Learn More About How Well Aficamten Works in Japanese Participants With Symptomatic Obstructive Hypertrophic Cardiomyopathy

Exclusion Criteria

• •Significant valvular heart disease (per investigator judgement)
• •1. Moderate-severe valvular aortic stenosis and/or regurgitation
• •2. Moderate-severe mitral regurgitation not due to systolic anterior motion of the mitral valve
• •Known or suspected infiltrative, genetic or storage disorder causing cardiac hypertrophy that mimics oHCM (e.g., Noonan syndrome, Fabry disease, amyloidosis)
• •History of LV systolic dysfunction (LVEF \<45%) or stress cardiomyopathy at any time during their clinical course
• •Documented paroxysmal atrial fibrillation during the screening period
• •Paroxysmal or persistent/permanent atrial fibrillation is only excluded IF:
• •Rhythm restoring treatment (e.g., direct-current cardioversion, atrial fibrillation ablation procedure, or antiarrhythmic therapy) has been required ≤ 6 months prior to screening
• •Rate control and anticoagulation have not been achieved for at least 6 months prior to screening
• •Has been treated with SRT (surgical myectomy or percutaneous alcohol septal ablation) or cannot postpone plans for SRT until after the study period
• •History of syncope or sustained ventricular tachyarrhythmia with exercise within 6 months prior to screening
• •Has received prior treatment with aficamten or mavacamten